Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous TILs in high-risk recurrent primary hepatocellular carcinoma
NCT04538313Phase 2Unknown
- Sponsor
- CAR-T (Shanghai) Biotechnology
- Start
- Aug 2020
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of autologous tumor-infiltrating lymphocytes in hepatocellular carcinoma (HCC), sponsored by CAR-T (Shanghai) Biotechnology. Status: unknown.
02
Drugs
autologous tumor-infiltrating lymphocytes
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04538313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04538313.